Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Response to rituximab in a child with neuroblastoma and opsoclonus‐myoclonus

2006; Wiley; Volume: 50; Issue: 2 Linguagem: Inglês

10.1002/pbc.20899

ISSN

1545-5017

Autores

Jessica F. Bell, Cassandra Moran, Julie Blatt,

Tópico(s)

Blood disorders and treatments

Resumo

Abstract Opsoclonus‐myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long‐term neurologic outcome. We present a case of a 19‐month‐old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab. Pediatr Blood Cancer 2008;50:370–371. © 2006 Wiley‐Liss, Inc.

Referência(s)